Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review

November 2021 | 39 pages | ID: K40CAE0A60CEN
GlobalData

Abstracts

Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Kuros Biosciences AG (Kuros Biosciences) is a developer of products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products are being developed for spinal fusion, fracture repair and as surgical sealants. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal. The company operates in Schlieren, Switzerland; Bilthoven, the Netherlands; Burlington, USA and in Konstanz, Germany. Kuros Biosciences is headquartered in Schlieren, Switzerland.

Kuros Biosciences AG Key Recent Developments

Mar 18,2021: Kuros Biosciences Reports Results for the Full Year 2020
Mar 10,2021: Kuros Biosciences to present at upcoming clinical and investor conferences
Aug 12,2020: Kuros Biosciences reports results for first half 2020
Mar 26,2020: Kuros Biosciences reports results for the full year 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Kuros Biosciences AG - Key Facts
Kuros Biosciences AG - Key Employees
Kuros Biosciences AG - Key Employee Biographies
Kuros Biosciences AG - Major Products and Services
Kuros Biosciences AG - History
Kuros Biosciences AG - Company Statement
Kuros Biosciences AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Kuros Biosciences AG - Business Description
Geographical Segment: Other
Performance
Geographical Segment: The U.S
Performance
Geographical Segment: The UK
Performance
Kuros Biosciences AG - SWOT Analysis
SWOT Analysis - Overview
Kuros Biosciences AG - Strengths
Kuros Biosciences AG - Weaknesses
Kuros Biosciences AG - Opportunities
Kuros Biosciences AG - Threats
Kuros Biosciences AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kuros Biosciences AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Mar 18, 2021: Kuros Biosciences Reports Results for the Full Year 2020
Mar 10, 2021: Kuros Biosciences to present at upcoming clinical and investor conferences
Aug 12, 2020: Kuros Biosciences reports results for first half 2020
Mar 26, 2020: Kuros Biosciences reports results for the full year 2019

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Kuros Biosciences AG, Key Facts
Kuros Biosciences AG, Key Employees
Kuros Biosciences AG, Key Employee Biographies
Kuros Biosciences AG, Major Products and Services
Kuros Biosciences AG, History
Kuros Biosciences AG, Subsidiaries
Kuros Biosciences AG, Key Competitors
Kuros Biosciences AG, Ratios based on current share price
Kuros Biosciences AG, Annual Ratios
Kuros Biosciences AG, Annual Ratios (Cont...1)
Kuros Biosciences AG, Interim Ratios
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Kuros Biosciences AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Kuros Biosciences AG, Performance Chart (2016 - 2020)
Kuros Biosciences AG, Ratio Charts
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Kuros Biosciences AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021